Pancreas
J Clin Gastroenterol. 2022;56(3):e227–31
Does hyperlipasemia predict worse clinical outcomes in COVID-19? A multicenter retrospective cohort study
Goal: The authors aimed to perform a multicenter retrospective cohort study to determine if elevated serum lipase determines clinical outcomes in patients with coronavirus disease 2019 (COVID-19).
Background: Several cases of acute pancreatitis have recently been reported in association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most of the evidence is based on elevated serum lipase values without objective demonstration of pancreatic inflammation or necrosis.
Materials and methods: A population-based, multicenter, retrospective cohort study utilizing TriNetX was performed to obtain aggregated health records of approx. 69 million patients from 49 health care organizations from January 1, 2020, to December 31, 2020. Adult patients (≥ 18 years) diagnosed with COVID-19 were identified using appropriate International Classification of Diseases, 10th Revision (ICD-10) codes and were stratified into 2 groups, with elevated (≥ 180 U/l) and with normal (≤ 80 U/l) serum lipase. The primary outcome was 30-day mortality; other outcomes were 30-day rehospitalization, need for mechanical ventilation, need for vasopressor use, acute kidney injury.
Results: A total of 435,731 adult patients with COVID-19 were identified, and 1406 of them had elevated serum lipase which was associated with higher 30-day mortality (risk ratio [RR] = 1.53, p < 0.001), risk of acute kidney injury (RR = 1.5, p = 0.003), and vasopressor use (RR = 1.69, p < 0.001) without any difference in 30-day rehospitalization (RR = 0.98, p = 0.54), or need for mechanical ventilation (RR = 1.20, p = 0.26). The negative predictive value of normal serum lipase for 3-month mortality in patients with COVID-19 was 91%.
Conclusions: Patients with COVID-19 who have elevated serum lipase experience worse clinical outcomes even in the absence of acute pancreatitis. If these findings can be replicated in prospective studies, serum lipase can be utilized as a marker of disease severity in patients with COVID-19.